You are here: Industry Insights > psoriasis

News List

Novartis looks past psoriasis for even bigger Cosentyx growth frontier fiercepharma
November 15, 2017
Novartis’ Cosentyx currently leads a crop of next-gen immunology products from a who’s who of Big Pharma. And the Swiss drugmaker intends to keep it that way.
AbbVie’s psoriasis drug smashes all endpoints pharmafile
October 27, 2017
AbbVie already know well what it’s like to have a lead candidate in the psoriasis field, after having Humira sat at the top of the heap for years.
Glenmark launches oral drug for psoriasis treatment expressbpd
October 25, 2017
Glenmark Pharmaceuticals has launched Apremilast, the first advanced oral systemic treatment for psoriasis in India.
MC2 Therapeutics A/S Announces First Patient Dosed in Pivotal US Phase 3 Trial in Psoriasis Vulgaris b3cnewswire
October 13, 2017
MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that first patient has been dosed in its pivotal Phase 3 clinical trial assessing the safety and efficacy of MC2-01 Cream (calcipotriene and betamethasone
Janssen’s guselkumab shows long-term benefit in psoriasis pharmatimes
September 20, 2017
Janssen has unveiled new data showing consistent rates of skin clearance with guselkumab treatment among patients with moderate to severe plaque psoriasis.
Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy worldpharmanews
September 18, 2017
Novartis has announced, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years[1]
NICE backs new treatment option for psoriasis pharmatimes
August 08, 2017
The National Institute for Health and Care Excellence has issued draft guidelines backing NHS use of Almirall’s Skilarence to treat moderate to severe plaque psoriasis.
LEO Pharma gets EC nod for its first and only biologic Kyntheum that targets the IL-17 receptor biospectrumasia
July 27, 2017
By specifically binding to the receptor on skin cells rather than targeting free floating inflammatory mediators, brodalumab blocks the biological activity of several pro-inflammatory IL-17 cytokines involved in psoriasis plaque formation.
EU approves LEO Pharma’s psoriasis biologic pharmatimes
July 21, 2017
A new treatment option has been approved in the European Union for patients with psoriasis，，
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing worldpharmanews
July 18, 2017
Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis[1].

Previous page 1 2 3 4 5 6 7 8 9 10 Next page